drugset / Trial / NCT00622635

A Crossover Study to Determine the 24 Hour Lung Function Profile of Indacaterol in Patients With Moderate-to-severe Chronic Obstructive Pulmonary Disease (COPD)

NCT00622635

Phase 3 Completed 68 enrolled Novartis Pharmaceuticals
RandomizedCrossoverQuadruple-blindTreatment

Summary

This study was conducted to provide detailed information on the efficacy of indacaterol in terms of its effect on spirometry assessed forced expiratory volume in 1 second (FEV1) over a 24 hour time period.

Timeline

Start
2008-01
Primary completion
2008-07
Completion
2008-07

Drugs

EvaluationDrugModalityDoseRoute
Subject Indacaterol Other / unclassified 300 ug Inhaled
Subject Salmeterol Other / unclassified 50 ug Inhaled